| Bioactivity | aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells[1]. |
| Shortening | Ac-RRWPR-S5-ILD-S5-HVRRVWR-NH2 |
| Formula | C111H178N40O20.xC2HF3O2 |
| Molar Mass | 2392.86 (free base) |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Grossmann TN, et al. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):17942-7. |
aStAx-35R TFA
CAS: F: C111H178N40O20.xC2HF3O2 W: 2392.86 (free base)
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhib
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.